Peter Laszlo Kanizsai
|Albertus Beishuizen (the Netherlands)
|Mike Broyles (USA)
|Ricard Ferrer (Spain)
|Gaëtan Gavazzi (France)
|Eric Howard Gluck (USA)
|Juan González del Castillo (Spain)
|Jens Ulrik Stæhr Jensen (Denmark)
|Andrea Kwa (Singapore)
|Stephen Kidd (UK)
|Charles-Edouard Luyt (France)
|Michael Oppert (Germany)
|Mario Plebani (Italy)
|Philipp Schütz (Switzerland)
|Sergey Shlyapnikov (Russian Federation)
|Giulio Toccafondi (Italy)
|Jennifer Townsend (USA)
|Tobias Welte (Germany)
How to Join
Members of an ISAC Member Society are eligible to join any of our Working Groups. If you are a member and would like to join this group, please contact Fee Johnstone, ISAC Executive Assistant at email@example.com.
Aims and Objectives
Given the amount of research and investment in the field of novel diagnostics and biomarkers, it is predicted that provision of medicine in the future will be transformed. The main aims of novel diagnostics and biomarkers are not only to recognise infection and/or sepsis, but also to assist in triaging patients with regards to avoiding admission, ward admission, intensive care admission and even prognosis and predicting outcome.
Another aspect of novel diagnostics and biomarkers is to improve antibiotic stewardship in clinical settings. Therefore, this working group aims to:
- Organise educational meetings and provide educational material on the application of novel diagnostics and biomarkers in clinical practice e.g. antibiotic stewardship and/or triaging.
- Promote a “network” to collect data from those centres that use novel diagnostics and/or biomarkers and audits of good practice with regards to novel diagnostics and biomarkers.
- Develop practice guidelines or recommendations for a correct approach in applying these novel technologies and biomarkers in clinical practice.
We hope that the group’s work will result in a closer collaboration among international experts who can bridge the gap between studies, clinical applications and patients’ needs, thereby improving not only antibiotic stewardship and better quality of patient care, but also in reducing the cost to healthcare systems across the world.
Future / Ongoing Activities
Our ideas for the coming years are to organise coordinated (reviews or audits or quality improvement projects or even video lectures) related to biomarker incorporation to clinical practice for example in any of the following areas:
• How to make sure point of care tests are complementary to medical microbiology and part of their overall diagnostic package. This can be challenging to achieve; however, it can be done through coordination and also registration for surveillance among the working group.
• When to use biomarker testing versus targeted testing. (Writing reviews)
• How does lateral flow assays impact on what we do clinically? (Writing reviews)
• For resistance markers, do we still need to know the bug? (Writing review)
Survey on impact of rapid diagnostics in infection
Hot topics on procalcitonin use in clinical practice, can it help antibiotic stewardship?
Saeed K, del Castillo JG, Backous C et al.
Int J Antimicrob Agents. 2019;54:686-696.
Last updated: February 7th-2020